# Sensus Healthcare, Inc.

**SRTS**

Nasdaq; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0001494891

**B**

**second fifth of 370 graded peers in healthcare**

rank 99 of 370; percentile 26.6; sampling error 2.5 points; lower is stronger

A B C D E

**B, the elk**



| Scoreboard | |
|---|---|
| **Profitability** | C/D<br>percentile 57.8 |
| **Solvency** | A<br>percentile 11.2 |
| **Growth and financing** | C<br>percentile 51.8 |
| **Reliability** | 0.83 AUC<br>filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025 |
| **Peer failure rate** | 1.07% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $12.5M to $120M assets<br>total assets $53.0M |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | none triggered<br>not computable: distress, fortress balance sheet |
| **Inputs computable** | 8 of 14 |
| **Graded from** | filings received through Mar 4, 2026<br>233 days before the rescan; latest periodic filing 10-Q received Aug 14, 2026 |
| **Last close** | $2.86<br>2026-10-22; market equity $47.1M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 4, 2026*

its subsidiaries, Sensus Medical Devices Ltd. and Sensus Healthcare Services, LLC, unless the context otherwise indicates, "Sensus," "we," "us," "our," or the "Company") is a medical device company committed to providing highly effective, non-invasive treatments for non-melanoma skin cancer (NMSC) and post-surgical keloid scar prevention. The Company uses a proprietary low-energy X-ray technology known as superficial radiation therapy ("SRT"), which is based on decades of dedicated research and development, and has successfully incorporated SRT into a portfolio of treatment devices: the SRT-100TM, SRT-100+TM and SRT-100 VisionTM.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 57.8** | | | | | | |
| Gross profitability | 22.4% | 32.3% | | 60.3 | 371 | 2025-12-31 |
| Return on invested capital | not computable | 9.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | |
|---|---|---|---|---|---|
| Accruals ratio | (14.3%) | (6.6%) | 31.3 | 812 | 2025-12-31 |
| Gross margin stability, five years | 7.9 pts | 2.8 pts | 81.7 | 242 | 2025-12-31 |
| **Solvency, sleeve percentile 11.2** | | | | | |
| Twelve-month failure probability | not computable | 0.06% | | | |
| *latest liabilities, cash plus short-term investments, book equity, and shares are required* | | | | | |
| Altman Z double-prime | 14.36 | (0.30) | 5.2 | 757 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | |
| *one or more required annual facts are missing* | | | | | |
| Interest coverage | not computable | (4.51x) | | | |
| *latest aligned inputs end 2024-12-31; latest annual assets end 2025-12-31* | | | | | |
| Current ratio | 9.72x | 2.96x | 17.3 | 840 | 2025-12-31 |
| **Growth and financing, sleeve percentile 51.8** | | | | | |
| Revenue growth, three-year compound | (14.9%) | 10.1% | 87.4 | 414 | 2025-12-31 |
| Free cash flow growth, three-year compound | not computable | 10.9% | | | |
| *current FCF must be positive and base FCF must exceed $100,000* | | | | | |
| Reinvestment rate | not computable | 37.1% | | | |
| *NOPAT must exceed $100,000* | | | | | |
| Asset growth, three years | (2.2%) | 2.1% | 56.5 | 705 | 2025-12-31 |
| Net share issuance, one year | (0.2%) | 2.4% | 11.4 | 633 | 2026-02-24 |

## Among 370 peers

*healthcare; letters are fifths of this list*




*Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.*

| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 94 | NeuroPace Inc. (NPCE) | 25.2 | B | |
| 95 | GE HealthCare Technologies Inc. (GEHC) | 25.5 | B | |
| 96 | Mirum Pharmaceuticals, Inc. (MIRM) | 25.7 | B | |
| 97 | Phibro Animal Health Corp. (PAHC) | 26.0 | B | |
| 98 | Zoetis Inc. (ZTS) | 26.3 | B | |
| 99 | Sensus Healthcare, Inc. (SRTS) | 26.6 | B | |
| 100 | Lineage Cell Therapeutics, Inc. (LCTX) | 26.8 | B | |
| 101 | Travere Therapeutics, Inc. (TVTX) | 27.1 | B | |
| 102 | Tela Bio, Inc. (TELA) | 27.4 | B | fortress balance sheet |
| 103 | Alphatec Holdings, Inc. (ATEC) | 27.6 | B | |
| 104 | Agape ATP Corp. (ATPC) | 27.9 | B | late filer |

## What the price implies

*at the 2026-10-22 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | 12.7% | 8.0% | 53 |
| Distance from 52-week high | (45.8%) | (29.6%) | 30 |
| EBIT to enterprise value | not computable | (1.5%) | |
| Free cash flow yield | 0.7% | (0.9%) | 58 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | |
|---|---|---|---|
| Book value to price | 0.78 | 0.27 | 80 |
| Sales to price | 0.58 | 0.30 | 71 |
| Composite equity issuance, five years | (0.1%) | 20.5% | 27 |
| Relative strength against the sector, log excess return | (0.09) | (0.13) | 53 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | pass |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | pass |
| No new shares issued | pass |
| Gross margin improved | fail |
| Asset turnover improved | fail |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $15.2M |
| Operating cash flow, four quarters | -$6.8M |
| Months of runway | 26.8 |
| Days since last periodic filing | 70 (10-Q received Aug 14, 2026) |
| Median daily dollar volume, 63 sessions | $58,042 |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | gross profit | us-gaap:GrossProfit | $11.9M | 2025-12-31 | 2026-03-04 | 10-K | 26-000435 |
| 2 | assets | us-gaap:Assets | $53.0M | 2025-12-31 | 2026-03-04 | 10-K | 26-000435 |
| 3 | net income | us-gaap:NetIncomeLoss | -$7.7M | 2025-12-31 | 2026-03-04 | 10-K | 26-000435 |
| 4 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $528,000 | 2025-12-31 | 2026-03-04 | 10-K | 26-000435 |
| 5 | assets | us-gaap:Assets | $62.2M | 2024-12-31 | 2026-03-04 | 10-K | 26-000435 |
| 6 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $27.5M | 2025-12-31 | 2026-03-04 | 10-K | 26-000435 |
| 7 | gross profit | us-gaap:GrossProfit | $24.4M | 2024-12-31 | 2026-03-04 | 10-K | 26-000435 |
| 8 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $41.8M | 2024-12-31 | 2026-03-04 | 10-K | 26-000435 |
| 9 | gross profit | us-gaap:GrossProfit | $14.1M | 2023-12-31 | 2025-03-05 | 10-K | 25-000408 |
| 10 | revenue | us-gaap:Revenues | $24.4M | 2023-12-31 | 2025-03-05 | 10-K | 25-000408 |
| 11 | gross profit | us-gaap:GrossProfit | $29.6M | 2022-12-31 | 2024-03-15 | 10-K | 24-023093 |
| 12 | revenue | us-gaap:Revenues | $44.5M | 2022-12-31 | 2024-03-15 | 10-K | 24-023093 |
| 13 | gross profit | us-gaap:GrossProfit | $17.0M | 2021-12-31 | 2023-03-23 | 10-K | 23-022355 |
| 14 | revenue | us-gaap:Revenues | $27.0M | 2021-12-31 | 2023-03-23 | 10-K | 23-022355 |
| 15 | current assets | us-gaap:AssetsCurrent | $45.9M | 2025-12-31 | 2026-03-04 | 10-K | 26-000435 |
| 16 | current liabilities | us-gaap:LiabilitiesCurrent | $4.7M | 2025-12-31 | 2026-03-04 | 10-K | 26-000435 |
| 17 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | $5.7M | 2025-12-31 | 2026-03-04 | 10-K | 26-000435 |
| 18 | operating income | us-gaap:OperatingIncomeLoss | -$10.3M | 2025-12-31 | 2026-03-04 | 10-K | 26-000435 |
| 19 | book equity | us-gaap:StockholdersEquity | $48.1M | 2025-12-31 | 2026-03-04 | 10-K | 26-000435 |
| 20 | liabilities | us-gaap:Liabilities | $4.9M | 2025-12-31 | 2026-03-04 | 10-K | 26-000435 |
| 21 | operating income | us-gaap:OperatingIncomeLoss | $8.1M | 2024-12-31 | 2026-03-04 | 10-K | 26-000435 |
| 22 | interest expense | us-gaap:InterestExpense | -$932,000 | 2024-12-31 | 2025-03-05 | 10-K | 25-000408 |
| 23 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $196,000 | 2025-12-31 | 2026-03-04 | 10-K | 26-000435 |
| 24 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$831,000 | 2024-12-31 | 2026-03-04 | 10-K | 26-000435 |
| 25 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $276,000 | 2024-12-31 | 2026-03-04 | 10-K | 26-000435 |
| 26 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$2.1M | 2023-12-31 | 2025-03-05 | 10-K | 25-000408 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| 27 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $229,000 | 2023-12-31 | 2025-03-05 | 10-K | 25-000408 |
| 28 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$1.4M | 2022-12-31 | 2024-03-15 | 10-K | 24-023093 |
| 29 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $159,000 | 2022-12-31 | 2024-03-15 | 10-K | 24-023093 |
| 30 | depreciation amortization | us-gaap:Depreciation | $386,000 | 2025-12-31 | 2026-03-04 | 10-K | 26-000435 |
| 31 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$9.6M | 2025-12-31 | 2026-03-04 | 10-K | 26-000435 |
| 32 | income tax | us-gaap:IncomeTaxExpenseBenefit | -$1.9M | 2025-12-31 | 2026-03-04 | 10-K | 26-000435 |
| 33 | current assets | us-gaap:AssetsCurrent | $56.7M | 2024-12-31 | 2026-03-04 | 10-K | 26-000435 |
| 34 | current liabilities | us-gaap:LiabilitiesCurrent | $5.9M | 2024-12-31 | 2026-03-04 | 10-K | 26-000435 |
| 35 | assets | us-gaap:Assets | $53.7M | 2023-12-31 | 2025-03-05 | 10-K | 25-000408 |
| 36 | assets | us-gaap:Assets | $56.7M | 2022-12-31 | 2024-03-15 | 10-K | 24-023093 |
| 37 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 16,462,059 | 2026-02-24 | 2026-03-04 | 10-K | 26-000435 |
| 38 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 16,495,396 | 2025-02-12 | 2025-03-05 | 10-K | 25-000408 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.